TG and cancer: Thus, Table 4 shows the 52 pathways targeted and modulated by the selected miRNAs that are involved in both tumor development (e.g., proteoglycans in cancer (hsa05205), PI3K-Akt signaling pathway (hsa04151), Pathways in cancer (hsa05200), and Transcriptional misregulation in cancer (hsa05202)), hormonal imbalance (e.g., estrogen signaling pathway (hsa04915), neurotrophin signaling pathway (hsa04722), and thyroid hormone signaling pathway (hsa04919)), and neurodegenerative diseases (e.g., neurotrophin signaling pathway (hsa04722), and Axon guidance (hsa04360)) (Table 4).